Royalty Pharma PLC $RPRX Stock Holdings Lowered by AlTi Global Inc.

AlTi Global Inc. reduced its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 21.7% during the 3rd quarter, Holdings Channel reports. The fund owned 70,402 shares of the biopharmaceutical company’s stock after selling 19,544 shares during the quarter. AlTi Global Inc.’s holdings in Royalty Pharma were worth $2,484,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC increased its holdings in shares of Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 790 shares during the period. Alps Advisors Inc. acquired a new position in shares of Royalty Pharma during the third quarter valued at approximately $19,514,000. MMA Asset Management LLC raised its holdings in Royalty Pharma by 56.1% during the third quarter. MMA Asset Management LLC now owns 13,809 shares of the biopharmaceutical company’s stock worth $487,000 after purchasing an additional 4,960 shares in the last quarter. C WorldWide Group Holding A S lifted its position in Royalty Pharma by 4.3% in the third quarter. C WorldWide Group Holding A S now owns 654,457 shares of the biopharmaceutical company’s stock worth $23,089,000 after purchasing an additional 27,089 shares during the period. Finally, ABN AMRO Bank N.V. lifted its position in Royalty Pharma by 12.5% in the third quarter. ABN AMRO Bank N.V. now owns 38,700 shares of the biopharmaceutical company’s stock worth $1,361,000 after purchasing an additional 4,306 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Insider Buying and Selling

In other Royalty Pharma news, EVP George W. Lloyd sold 132,426 shares of the company’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $38.34, for a total transaction of $5,077,212.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Terrance P. Coyne sold 114,954 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $42.84, for a total value of $4,924,629.36. Following the completion of the sale, the chief financial officer directly owned 23,972 shares in the company, valued at approximately $1,026,960.48. This represents a 82.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 1,309,216 shares of company stock worth $52,015,364 over the last three months. 18.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RPRX shares. TD Cowen reissued a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Royalty Pharma in a report on Thursday, January 22nd. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. UBS Group upgraded Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price target for the company in a research report on Friday, January 30th. Finally, Leerink Partners set a $45.00 price objective on shares of Royalty Pharma in a research note on Thursday, December 11th. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, Royalty Pharma has an average rating of “Moderate Buy” and an average price target of $47.50.

Royalty Pharma Stock Up 0.4%

RPRX opened at $44.21 on Wednesday. The company has a market capitalization of $25.52 billion, a PE ratio of 33.49, a price-to-earnings-growth ratio of 1.68 and a beta of 0.42. The company has a debt-to-equity ratio of 0.89, a current ratio of 3.48 and a quick ratio of 3.48. Royalty Pharma PLC has a fifty-two week low of $29.66 and a fifty-two week high of $44.92. The business has a 50-day moving average of $40.09 and a 200-day moving average of $38.12.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th will be issued a dividend of $0.235 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.1%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. Royalty Pharma’s payout ratio is currently 66.67%.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.